Postoperative HypoparathyroidismPRESSPARNCT07491601
PRESS -PAR: Early Detection and PREvention of Symptomatic postSurgical hypoPARathyroidism After Thyroid Surgery"
A study testing Active vitamin D and Calcium in people with Postoperative Hypoparathyroidism and Postsurgical Hypoparathyroidism, run by Nicolas Schlegel at 1 site in Germany.
Trial summary
This study aims to investigate whether an earlier measurement of parathyroid hormone can reduce the number of patients who develop symptomatic hypoparathyroidism. This will provide evidence for a clear algorithm to address this issue after thyroid surgery. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Postoperative Hypoparathyroidism, Postsurgical Hypoparathyroidism, Hypoparathyroidism Post-surgical
- What is being tested?
- Active vitamin D and Calcium
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 336 participants
- Where
- 1 siteGermany
- Study dates
- 8 Jan 2025to 31 Dec 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥ 18 years
- Thyroidectomy or bilateral thyroid resection of any indication
- Written informed consent obtained after detailed patient information and provision of an information sheet
Who cannot join
- Age ≤ 18 years
- Concomitant parathyroid disease (primary or secondary hyperparathyroidism, pre-existing hypoparathyroidism of any cause)
- Previous surgery in the neck region
- Pregnancy or breastfeeding
- Inability to attend study visits
- Participation in another study that interferes with the endpoints
- Missing or inadequate patient information
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Germany1 site, 1 recruiting
- Recruiting
Dept. Surgery I; University Hospital Wuerzburg
Würzburg, Bavaria, 97080
Nicole Kirschbauer, Study Nurse, +49 931 201 31173, kirschbauer_n@ukw.de
Ruth G Gubba, MD, +49 931 201 31176, Gubba_R@ukw.de
About this study
This study aims to investigate whether an earlier measurement of parathyroid hormone can reduce the number of patients who develop symptomatic hypoparathyroidism. This will provide evidence for a clear algorithm to address this issue after thyroid surgery. It will lead to an improvement in quality of life and a reduction in the distress experienced by affected patients. In addition, it is conceivable that patients' hospital stay could be shortened.
Read the detailed description
Information and Recruitment First, patients who meet the inclusion criteria and do not meet any exclusion criteria will be identified in our surgical-endocrine outpatient clinic. All concomitant medications, particularly any pre-existing vitamin D intake, will be documented. As part of the routine blood sampling, parathyroid hormone, calcium, and vitamin D are determined according to the guidelines in order to detect any pre-existing parathyroid disorders (exclusion criteria). After informing the patient about the indication, necessity, and risks of the planned procedure, an additional explanation is given regarding the possibility of participating in the study.
Both written and oral information about the study will be provided to the patient.
Study Timeline The planned recruitment period is 3 years, followed by a 6-month follow-up. Study Visits After patients are enrolled in the study, baseline characteristics are collected, as well as quality-of-life data using standardized questionnaires (SF-36, STAI-G) and the Health Patient Questionnaire (HPQ28), along with a modified version of the "Hypoparathyroidism Patient Experience Scale - Symptom (HPES)." This questionnaire is included in the appendices and has so far been validated for chronic hypoparathyroidism. Validation for the acute setting is currently being carried out through targeted surveys of our own patient cohort during routine perioperative visits.
Postoperative clinical visits take place on days 0, 1, and 2 in accordance with current clinical standards. In the intervention group, parathyroid hormone is measured directly postoperatively within the first 3 hours after surgery. In the control group, this measurement is performed on the first postoperative day (within 24 hours after surgery) during routine blood sampling. This measurement is also carried out at the same time point-on the first postoperative day-in the intervention group. In both groups, vitamin D and calcium supplementation is initiated if the parathyroid hormone level falls below the normal range. On postoperative days 1 and 2, both groups complete the HPES, HPQ28, and STAI-G questionnaires.
As part of the study, an additional clinical visit and laboratory testing is performed after discharge on days 8-10. This additional visit is normally conducted only in patients who showed abnormalities during their hospital stay, such as low calcium or parathyroid hormone levels.
Finally, after 6 months, patients are contacted again by telephone to assess the secondary endpoints, including a renewed evaluation of quality of life. The telephone follow-up also determines whether patients are still experiencing any symptoms at that time and whether continued vitamin D and calcium supplementation is necessary. For patients who did not develop postoperative hypoparathyroidism, the goal is to exclude the possibility that delayed symptoms have occurred (even though this is rare). Furthermore, it should be clarified whether early intervention to prevent symptomatic hypoparathyroidism leads to better long-term quality of life.
Patients in whom the condition persists long-term-i.e., after 6 months-will, as in current clinical routine, be referred to endocrinology for ongoing therapy and monitoring. There is already close collaboration with Prof. Dr. Stefanie Hahner and Prof. Dr. Carmina Fuß in endocrinology. This follow-up is no longer part of the study.
Together with the collaborating partners from endocrinology measurements of parathyroid hormone and calcium levels will be performed according to the UKW standard in the central laboratory and in the endocrinology laboratory. The standards and measurement methods in both laboratories are well established. No technical changes are expected in the coming years, as new devices for parathyroid hormone testing were recently acquired by the endocrinology department.
Randomization Randomization is carried out during or shortly after the surgical procedure by staff of the Surgical Study Center Würzburg. Randomization is performed using the platform "Randomizer.at." Registration takes place after approval by the ethics committee.
- Conditions
- Postoperative Hypoparathyroidism, Postsurgical Hypoparathyroidism, Hypoparathyroidism Post-surgical
- Being tested
- Active vitamin D, Calcium
- Keywords
- Thyroid surgery, Perioperative medicine, Postoperative Hypoparathyroidism, Calcium supplementation, Active Vitamin D supplementation, Quality of life after surgery, Post-surgical Hypoparathyroidism
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Active vitamin DDrug
Application if parathyroid hormone level falls below normal
CalciumDrug
Administered if parathyroid hormone level falls below normal
| Study group | Role | What they receive |
|---|---|---|
| Standard of Care | Sham comparator | Measurement of parathormone levels and calcium on postoperative day 1 (beginning at day 1 after surgery) Receives: Drug: Active vitamin D; Drug: Calcium |
| Early postoperative sampling of parathyroid hormone and Calcium (within 1-3 hours after surgery)) | Experimental | Measurement of parahthyroid hormone and calcium within 1-3 hours post surgery Receives: Drug: Active vitamin D; Drug: Calcium |
What is being measured
The primary outcome is the main question the study is designed to answer.
Symptomatic hypoparathyroidism (symptom score) with hypocalcemia
Symptomatic hypoparathyroidism is defined as the presence of one or more symptoms reported in the questionnaire.
Measured: within hospital stay (0-48hours after bilateral thyroid surgery)
Secondary outcomes (4)
Length of Hospital stay
Duration of hospital stay
Measured: up to 14 days after surgery, on average 2 days
Initation of substitution therapy with active vitamin D and calcium
Duration of supplementation based on symtptoms and biochemical restoration of PTH levels
Measured: up to 6 months after surgery
Quality of life with changes in psychological burden
Measurement of Quality of Life using Short Form (36) Healthy Survey (SF36), State-Trait Anxiety Inventory- German version (STAI-G) and Hypoparathyroidism Patient Questionnaire 28 (HPQ28)
Measured: up to 1 day before surgery or earlier and after 6 months after surgery
Patient readmission due to hypocalcemia with or without symptoms
Patients with problems after discharge who require readmission
Measured: up to 6 months after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Mar 2026
- Study start8 Jan 2025
- Primary completion31 Dec 2028 (estimated)
- Study completion31 Dec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Postoperative HypoparathyroidismStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- This is a multicenter, two-arm, randomized interventional study. It is important to emphasize that patients receive the same diagnostics and treatment as currently standard practice. The only difference is that these are either performed earlier, depending on allocation to one of the study arms, or carried out at the usual time according to current practice.
- Masking
- None (open label)
- Enrolment
- 336 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Nicolas Schlegel
- Sponsor type
- University, hospital or other
- Collaborators
- University of Wuerzburg
- Responsible party
- Sponsor-investigator, Nicolas Schlegel, University of Wuerzburg
- Investigators
- Nicolas Schlegel, Prof. Dr. (MD), Principal investigator, Wuerzburg University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07491601
- Sponsor's protocol ID
- Version II /05- 2024
- Acronym
- PRESSPAR
- Status last verified
- Dec 2025
- First submitted
- 5 Dec 2025
- Last updated
- 24 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared due to data protection regulations and lack of participant consent for data sharing
Study at a glance
From the registry record, last updated by the sponsor on 24 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- PRESS -PAR: Early Detection and PREvention of Symptomatic postSurgical hypoPARathyroidism After Thyroid Surgery"
- ClinicalTrials.gov ID
- NCT07491601
- Acronym / sponsor ID
- PRESSPAR / Version II /05- 2024
- Conditions
- Postoperative Hypoparathyroidism, Postsurgical Hypoparathyroidism, Hypoparathyroidism Post-surgical
- Keywords
- Thyroid surgery, Perioperative medicine, Postoperative Hypoparathyroidism, Calcium supplementation, Active Vitamin D supplementation, Quality of life after surgery, Post-surgical Hypoparathyroidism
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 336 participants (estimated)
- Lead sponsor
- Nicolas SchlegelUniversity, hospital or other
- Collaborators
- University of Wuerzburg
- Study start
- 8 Jan 2025 (actual)
- Primary completion
- 31 Dec 2028 (estimated)
- Study completion
- 31 Dec 2029 (estimated)
- First posted
- 24 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to investigate whether an earlier measurement of parathyroid hormone can reduce the number of patients who develop symptomatic hypoparathyroidism. This will provide evidence for a clear algorithm to address this issue after thyroid surgery. It will lead to an improvement in quality of life and a reduction in the distress experienced by affected patients. In addition, it is conceivable that patients' hospital stay could be shortened.
Detailed description
Information and Recruitment First, patients who meet the inclusion criteria and do not meet any exclusion criteria will be identified in our surgical-endocrine outpatient clinic. All concomitant medications, particularly any pre-existing vitamin D intake, will be documented. As part of the routine blood sampling, parathyroid hormone, calcium, and vitamin D are determined according to the guidelines in order to detect any pre-existing parathyroid disorders (exclusion criteria). After informing the patient about the indication, necessity, and risks of the planned procedure, an additional explanation is given regarding the possibility of participating in the study.
Both written and oral information about the study will be provided to the patient.
Study Timeline The planned recruitment period is 3 years, followed by a 6-month follow-up. Study Visits After patients are enrolled in the study, baseline characteristics are collected, as well as quality-of-life data using standardized questionnaires (SF-36, STAI-G) and the Health Patient Questionnaire (HPQ28), along with a modified version of the "Hypoparathyroidism Patient Experience Scale - Symptom (HPES)." This questionnaire is included in the appendices and has so far been validated for chronic hypoparathyroidism. Validation for the acute setting is currently being carried out through targeted surveys of our own patient cohort during routine perioperative visits.
Postoperative clinical visits take place on days 0, 1, and 2 in accordance with current clinical standards. In the intervention group, parathyroid hormone is measured directly postoperatively within the first 3 hours after surgery. In the control group, this measurement is performed on the first postoperative day (within 24 hours after surgery) during routine blood sampling. This measurement is also carried out at the same time point-on the first postoperative day-in the intervention group. In both groups, vitamin D and calcium supplementation is initiated if the parathyroid hormone level falls below the normal range. On postoperative days 1 and 2, both groups complete the HPES, HPQ28, and STAI-G questionnaires.
As part of the study, an additional clinical visit and laboratory testing is performed after discharge on days 8-10. This additional visit is normally conducted only in patients who showed abnormalities during their hospital stay, such as low calcium or parathyroid hormone levels.
Finally, after 6 months, patients are contacted again by telephone to assess the secondary endpoints, including a renewed evaluation of quality of life. The telephone follow-up also determines whether patients are still experiencing any symptoms at that time and whether continued vitamin D and calcium supplementation is necessary. For patients who did not develop postoperative hypoparathyroidism, the goal is to exclude the possibility that delayed symptoms have occurred (even though this is rare). Furthermore, it should be clarified whether early intervention to prevent symptomatic hypoparathyroidism leads to better long-term quality of life.
Patients in whom the condition persists long-term-i.e., after 6 months-will, as in current clinical routine, be referred to endocrinology for ongoing therapy and monitoring. There is already close collaboration with Prof. Dr. Stefanie Hahner and Prof. Dr. Carmina Fuß in endocrinology. This follow-up is no longer part of the study.
Together with the collaborating partners from endocrinology measurements of parathyroid hormone and calcium levels will be performed according to the UKW standard in the central laboratory and in the endocrinology laboratory. The standards and measurement methods in both laboratories are well established. No technical changes are expected in the coming years, as new devices for parathyroid hormone testing were recently acquired by the endocrinology department.
Randomization Randomization is carried out during or shortly after the surgical procedure by staff of the Surgical Study Center Würzburg. Randomization is performed using the platform "Randomizer.at." Registration takes place after approval by the ethics committee.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- This is a multicenter, two-arm, randomized interventional study. It is important to emphasize that patients receive the same diagnostics and treatment as currently standard practice. The only difference is that these are either performed earlier, depending on allocation to one of the study arms, or carried out at the usual time according to current practice.
| Arm | Type | Receives |
|---|---|---|
| Standard of Care | Sham comparator | Drug: Active vitamin D, Drug: CalciumMeasurement of parathormone levels and calcium on postoperative day 1 (beginning at day 1 after surgery) |
| Early postoperative sampling of parathyroid hormone and Calcium (within 1-3 hours after surgery)) | Experimental | Drug: Active vitamin D, Drug: CalciumMeasurement of parahthyroid hormone and calcium within 1-3 hours post surgery |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Age ≥ 18 years
- Thyroidectomy or bilateral thyroid resection of any indication
- Written informed consent obtained after detailed patient information and provision of an information sheet
Key exclusion criteria (7 listed)
- Age ≤ 18 years
- Concomitant parathyroid disease (primary or secondary hyperparathyroidism, pre-existing hypoparathyroidism of any cause)
- Previous surgery in the neck region
- Pregnancy or breastfeeding
- Inability to attend study visits
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Active vitamin DApplication if parathyroid hormone level falls below normal | Drug | Early postoperative sampling of parathyroid hormone and Calcium (within 1-3 hours after surgery)), Standard of Care |
| CalciumAdministered if parathyroid hormone level falls below normal | Drug | Early postoperative sampling of parathyroid hormone and Calcium (within 1-3 hours after surgery)), Standard of Care |
Primary outcome
Symptomatic hypoparathyroidism (symptom score) with hypocalcemia
Time frame: within hospital stay (0-48hours after bilateral thyroid surgery)
Symptomatic hypoparathyroidism is defined as the presence of one or more symptoms reported in the questionnaire.
4 secondary outcomes
Length of Hospital stay
Time frame: up to 14 days after surgery, on average 2 days
Initation of substitution therapy with active vitamin D and calcium
Time frame: up to 6 months after surgery
Quality of life with changes in psychological burden
Time frame: up to 1 day before surgery or earlier and after 6 months after surgery
Patient readmission due to hypocalcemia with or without symptoms
Time frame: up to 6 months after surgery
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Mar 2026.
- Individual participant dataSharing planned: No. Individual participant data will not be shared due to data protection regulations and lack of participant consent for data sharing
Related trials for Postoperative Hypoparathyroidism
Recruiting
NIRAF-Guided Parathyroid Identification During Thyroidectomy
Hypocalcemia, Hypoparathyroidism
RecruitingObservational study
Postoperative Hypocalcemia After Thyroidectomy
Thyroid Nodule, Thyroid Dysfunction
RecruitingObservational study
Risk Factors for Hypoparathyroidism Following Thyroidectomy
Post-Surgical Hypoparathyroidism
Recruiting
Calcium Replacement Therapy in Postoperative Hypoparathyroidism
Post-Thyroidectomy Hypoparathyroidism Treatment
Recruiting
Comparing PTeye-assisted Versus Conventional Total Thyroidectomy
Hypocalcemia, Parathyroid
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Nicolas Schlegel, Prof. Dr. (MD) principal investigator
Wuerzburg University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Active vitamin D and Calcium in people with Postoperative Hypoparathyroidism and Postsurgical Hypoparathyroidism, run by Nicolas Schlegel at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 24 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Nicolas Schlegel, Prof. Dr. (MD) (+49 931 201 38217, SCHLEGEL_N@ukw.de), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Symptomatic hypoparathyroidism (symptom score) with hypocalcemia (time frame: within hospital stay (0-48hours after bilateral thyroid surgery)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Mar 2026.